We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
-13.22%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$2.03B
AUM Growth
+$135M
Cap. Flow
+$465M
Cap. Flow %
22.9%
Top 10 Hldgs %
63.8%
Holding
57
New
6
Increased
19
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$187M
2
STE icon
Steris
STE
+$105M
3
CORT icon
Corcept Therapeutics
CORT
+$55M
4
CTLT
CATALENT, INC.
CTLT
+$36.8M
5
CABO icon
Cable One
CABO
+$36.4M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$29.9M
2
AAPL icon
Apple
AAPL
+$22.6M
3
INGN icon
Inogen
INGN
+$16.2M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$13.9M
5
NKTX icon
Nkarta
NKTX
+$8.06M

Sector Composition

Rank Sector Weight
1 Healthcare 58.54%
2 Technology 15.07%
3 Financials 6.4%
4 Communication Services 2.82%
5 Consumer Discretionary 2.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYT
26
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$14.5M 0.71%
4,840,413
– –
NARI
27
DELISTED
Inari Medical, Inc. Common Stock
NARI
$14.3M 0.7%
210,000
+86,878
+71% +$6.24M
VERV
28
DELISTED
Verve Therapeutics
VERV
$14.2M 0.7%
927,100
+177,100
+24% +$2.74M
ALNY icon
29
Alnylam Pharmaceuticals
ALNY
$29.3B
$12.4M 0.61%
84,800
+59,800
+239% +$8.48M
MORF
30
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$12.3M 0.6%
565,237
-1,069,574
-65% -$29.9M
ABCL icon
31
AbCellera Biologics
ABCL
$2.12B
$12M 0.59%
+1,126,915
New +$9.54M
CRNX icon
32
Crinetics Pharmaceuticals
CRNX
$8.92B
$11.8M 0.58%
631,627
+206,730
+49% +$4.13M
PHVS icon
33
Pharvaris
PHVS
$2.44B
$11.5M 0.57%
519,339
+3,018
+0.6% +$56.2K
INGN icon
34
Inogen
INGN
$164M
$11.2M 0.55%
462,949
-609,786
-57% -$16.2M
INSP icon
35
Inspire Medical Systems
INSP
$1.74B
$10.3M 0.51%
56,400
+14,952
+36% +$2.98M
KNTE
36
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$10.3M 0.51%
815,707
+191,471
+31% +$1.78M
SILK
37
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$10M 0.49%
275,511
-557
-0.2% -$20.2K
LVTX
38
DELISTED
LAVA Therapeutics
LVTX
$9.82M 0.48%
3,327,312
– –
BOLT icon
39
Bolt Biotherapeutics
BOLT
$7.78M
$9.19M 0.45%
225,200
– –
OKUR
40
OnKure Therapeutics
OKUR
$168M
$9.09M 0.45%
343,038
– –
RCKT icon
41
Rocket Pharmaceuticals
RCKT
$394M
$8.71M 0.43%
632,822
+20,000
+3% +$238K
TMCI icon
42
Treace Medical Concepts
TMCI
$309M
$8.44M 0.42%
588,308
+87,887
+18% +$1.48M
SPRB
43
Spruce Biosciences
SPRB
$129M
$7.86M 0.39%
60,191
– –
LUNG icon
44
Pulmonx
LUNG
$87.6M
$7.51M 0.37%
510,555
+100,400
+24% +$2.07M
AKUS
45
DELISTED
Akouos Inc
AKUS
$4.98M 0.25%
1,061,990
– –
RLYB icon
46
Rallybio
RLYB
$85.8M
$4.87M 0.24%
80,628
+26,135
+48% +$1.96M
UTRS
47
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
$4.82M 0.24%
102,445
– –
DMRA
48
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$4.32M 0.21%
99,912
– –
SPNE
49
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$3.92M 0.19%
694,677
-164,075
-19% -$1.43M
MQ icon
50
Marqeta
MQ
$1.66B
$3.58M 0.18%
110,390
– –
1
2
3

Similar funds

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.24B AUM 16.52% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
SPC
Stony Point Capital New York $1.24B AUM 32.69% 1-Year Est. Return
SC
Strategy Capital Los Altos, California $1.22B AUM 27.02% 1-Year Est. Return

Novo Holdings A/S's Q2 2022 Portfolio in Review

As of Q2 2022, Novo Holdings A/S held 57 positions worth $2.03B, up 7.1% from $1.9B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Novo Holdings A/S deployed $465M of net new capital in Q2 2022, opening 6 new positions and adding to 19 existing holdings. Its largest new stake was Stryker: 796,941 shares worth $159M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, up from 49% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Morphic Holding, Inc. Common Stock, an estimated $29.9M trimmed.

  • Novo Holdings A/S's largest Q2 2022 buy was Stryker: 796,941 shares worth $159M.
  • Novo Holdings A/S added most to CATALENT, INC. in Q2 2022, an estimated $36.8M increase.
  • Novo Holdings A/S's biggest Q2 2022 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $29.9M.
  • Novo Holdings A/S fully exited Iovance Biotherapeutics in Q2 2022, selling an estimated $13.9M.
  • Novo Holdings A/S's ten largest holdings make up 64% of its $2.03B portfolio in Q2 2022.
  • Novo Holdings A/S opened 6 new positions and closed 3 in Q2 2022.
  • Novo Holdings A/S's portfolio value rose 7.1% quarter-over-quarter to $2.03B.

Based on Novo Holdings A/S's 13F filing for Q2 2022, filed 15 Aug 2022.